Association of rapidly progressive moyamoya syndrome with bevacizumab treatment for glioblastoma in a child with neurofibromatosis type 1

Nicole J. Ullrich, Maryann Zimmerman, Edward Smith, Mira Irons, Karen Marcus, Mark W. Kieran

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

Neurofibromatosis type 1 is a common multisystemic disorder that can result in tumors of the central and peripheral nervous system. Individuals with neurofibromatosis type 1 are also at increased risk to develop moyamoya syndrome, which is a cerebrovascular condition that predisposes affected individuals to develop strokes as a result of progressive narrowing of the intracranial internal carotid arteries and failure of adequate blood supply through collateral vessels. We report a case of a young boy with neurofibromatosis type 1 with glioblastoma who developed rapidly progressive moyamoya vasculopathy after treatment with the angiogenesis inhibitor bevacizumab.

Original languageEnglish (US)
Pages (from-to)228-230
Number of pages3
JournalJournal of child neurology
Volume26
Issue number2
DOIs
StatePublished - Feb 2011
Externally publishedYes

Keywords

  • bevacizumab
  • glioblastoma
  • moyamoya
  • neurofibromatosis type 1

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Association of rapidly progressive moyamoya syndrome with bevacizumab treatment for glioblastoma in a child with neurofibromatosis type 1'. Together they form a unique fingerprint.

Cite this